Eefjan Breukink
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Eefjan Breukink has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Ben de Kruijff
Utrecht University
2 shared publications- Albert J. R. Heck
Utrecht University Padualaan 8
1 shared publication Ewa Swiezewska
1 shared publicationHester E. van Heusden
1 shared publicationLivia Brunner
1 shared publicationPauline J. Vollmerhaus
1 shared publication
Latest Publications
- 12 June 2006
- Published by Wiley in Molecular Microbiology
- Vol. 61 (2) , 271-273
A lesson in efficient killing from two‐component lantibiotics
Summary: The combined activity of the constituents of two‐component antibiotic systems is always significantly higher than the sum of the activities of the individual pieces. Understanding the principles behind this phenomenon might provide new ways to design new antibiotics. In this issue of Molecular Microbiology, Wiedemann and coworkers have made a big step towards understanding the mechanism of action of the two‐component lanthionine‐containing antibiotic lacticin 3147. It has now become clear that this two‐component system specifically targets the bacterial cell wall precursor Lipid II. This makes this essential bacterial lipid one of the most sought‐after targets in nature. Surprisingly, in view of its small size (MW 1875 Da), this is now the fifth different way that this key molecule is known to be targeted.
- 12 June 2006
- Published by Wiley in Molecular Microbiology
- Vol. 61 (2) , 271-273
A lesson in efficient killing from two‐component lantibiotics
Summary: The combined activity of the constituents of two‐component antibiotic systems is always significantly higher than the sum of the activities of the individual pieces. Understanding the principles behind this phenomenon might provide new ways to design new antibiotics. In this issue of Molecular Microbiology, Wiedemann and coworkers have made a big step towards understanding the mechanism of action of the two‐component lanthionine‐containing antibiotic lacticin 3147. It has now become clear that this two‐component system specifically targets the bacterial cell wall precursor Lipid II. This makes this essential bacterial lipid one of the most sought‐after targets in nature. Surprisingly, in view of its small size (MW 1875 Da), this is now the fifth different way that this key molecule is known to be targeted.
- Top Cited Papers
- 10 March 2006
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 5 (4) , 321-323
Lipid II as a target for antibiotics
Lipid II is a membrane-anchored cell-wall precursor that is essential for bacterial cell-wall biosynthesis. The effectiveness of targeting Lipid II as an antibacterial strategy is highlighted by the fact that it is the target for at least four different classes of antibiotic, including the clinically important glycopeptide antibiotic vancomycin. However, the growing problem of bacterial resistance to many current drugs, including vancomycin, has led to increasing interest in the therapeutic potential of other classes of compound that target Lipid II. Here, we review progress in understanding of the antibacterial activities of these compounds, which include lantibiotics, mannopeptimycins and ramoplanin, and consider factors that will be important in exploiting their potential as new treatments for bacterial infections.
- 10 March 2006
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 5 (4) , 321-323
Top Cited PapersLipid II as a target for antibiotics
Lipid II is a membrane-anchored cell-wall precursor that is essential for bacterial cell-wall biosynthesis. The effectiveness of targeting Lipid II as an antibacterial strategy is highlighted by the fact that it is the target for at least four different classes of antibiotic, including the clinically important glycopeptide antibiotic vancomycin. However, the growing problem of bacterial resistance to many current drugs, including vancomycin, has led to increasing interest in the therapeutic potential of other classes of compound that target Lipid II. Here, we review progress in understanding of the antibacterial activities of these compounds, which include lantibiotics, mannopeptimycins and ramoplanin, and consider factors that will be important in exploiting their potential as new treatments for bacterial infections.
- Open Access
- 1 May 2003
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 278 (22) , 19898-19903
Lipid II Is an Intrinsic Component of the Pore Induced by Nisin in Bacterial Membranes
- 1 May 2003
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 278 (22) , 19898-19903
Open AccessLipid II Is an Intrinsic Component of the Pore Induced by Nisin in Bacterial Membranes